$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000155837023005282 Filed on March 31, 2023

Income Statement

Concept	2022 Q4	2022	2021
Revenue	$16.40M	$75.74M	$68.79M
YoY Change	-10.24%	10.11%	50.86%
Cost Of Revenue	$7.718M	$30.78M	$32.08M
YoY Change	-18.97%	-4.08%	119.84%
Gross Profit	$8.686M	$44.97M	$36.71M
YoY Change	-0.74%	22.51%	18.39%
Gross Profit Margin	52.95%	59.37%	53.36%
Selling, General & Admin	$28.20M	$113.7M	$86.84M
YoY Change	1.81%	30.88%	41.98%
% of Gross Profit	324.65%	252.75%	236.58%
Research & Development	$35.12M	$134.9M	$128.9M
YoY Change	-18.43%	4.66%	101.01%
% of Gross Profit	404.34%	299.94%	351.06%
Depreciation & Amortization	$2.050M	$3.100M	$2.600M
YoY Change	63.87%	19.23%	13.04%
% of Gross Profit	23.6%	6.89%	7.08%
Operating Expenses	$63.32M	$248.5M	$215.7M
YoY Change	-10.5%	15.22%	72.19%
Operating Profit	-$54.63M	-$203.6M	-$188.5M
YoY Change	-11.88%	7.97%	100.0%
Interest Expense	-$2.997M	-$11.20M	$24.19M
YoY Change	-50.33%	-146.32%	-381.91%
% of Operating Profit
Other Income/Expense, Net	$635.0K	-$9.900M	$24.19M
YoY Change		-140.93%	-381.94%
Pretax Income	-$57.00M	-$213.5M	-$164.4M
YoY Change	-16.23%	29.88%	59.8%
Income Tax	$449.0K	$449.0K	$473.0K
% Of Pretax Income
Net Earnings	-$26.95M	-$86.58M	-$64.70M
YoY Change	-14.63%	33.8%	39.07%
Net Earnings / Revenue	-164.28%	-114.3%	-94.06%
Basic Earnings Per Share		-$0.97	-$0.79
Diluted Earnings Per Share	-$0.30	-$0.97	-$792.0K
COMMON SHARES
Basic Shares Outstanding		88.87M	81.70M
Diluted Shares Outstanding		88.87M	81.70M

Balance Sheet

Concept	2022 Q4	2022	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$178.3M	$178.3M	$305.7M
YoY Change	-41.69%	-41.69%	31.0%
Cash & Equivalents	$178.3M	$178.3M	$305.7M
Short-Term Investments
Other Short-Term Assets	$9.661M	$9.661M	$7.066M
YoY Change	36.73%	36.73%	5.46%
Inventory	$14.16M	$14.16M	$9.862M
Prepaid Expenses
Receivables	$28.21M	$28.21M	$23.11M
Other Receivables	$138.0K	$138.0K	$678.0K
Total Short-Term Assets	$230.4M	$230.4M	$346.5M
YoY Change	-33.49%	-33.49%	32.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.02M	$33.01M	$34.07M
YoY Change	-13.58%	-3.11%	5.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$973.0K	$3.661M	$3.418M
YoY Change	-18.78%	7.11%	26.59%
Total Long-Term Assets	$63.87M	$63.87M	$50.04M
YoY Change	27.63%	27.63%	-25.53%
TOTAL ASSETS
Total Short-Term Assets	$230.4M	$230.4M	$346.5M
Total Long-Term Assets	$63.87M	$63.87M	$50.04M
Total Assets	$294.3M	$294.3M	$396.5M
YoY Change	-25.78%	-25.78%	20.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$57.24M	$77.10M	$47.43M
YoY Change	20.69%	62.56%	132.5%
Accrued Expenses	$97.45M	$22.79M	$25.35M
YoY Change	7.49%	-10.09%	14.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.235M	$7.235M	$4.510M
YoY Change	60.42%	60.42%	-14.91%
Total Short-Term Liabilities	$127.7M	$127.7M	$101.0M
YoY Change	26.4%	26.4%	110.5%
LONG-TERM LIABILITIES
Long-Term Debt	$93.14M	$93.14M	$46.56M
YoY Change	100.03%	100.03%	-21.08%
Other Long-Term Liabilities	$1.847M	$23.42M	$23.02M
YoY Change	-9.15%	1.73%	-7.18%
Total Long-Term Liabilities	$1.847M	$116.6M	$69.58M
YoY Change	-9.15%	67.51%	-16.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$127.7M	$127.7M	$101.0M
Total Long-Term Liabilities	$1.847M	$116.6M	$69.58M
Total Liabilities	$244.3M	$252.6M	$287.8M
YoY Change	43.16%	-12.25%	25.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$634.2M
YoY Change	15.85%
Common Stock	$110.0K
YoY Change	8.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.72M	$41.72M	$108.7M
YoY Change
Total Liabilities & Shareholders Equity	$294.3M	$294.3M	$396.5M
YoY Change	-25.78%	-25.78%	20.59%

Cashflow Statement

Concept	2022 Q4	2022	2021
OPERATING ACTIVITIES
Net Income	-$26.95M	-$86.58M	-$64.70M
YoY Change	-14.63%	33.8%	39.07%
Depreciation, Depletion And Amortization	$2.050M	$3.100M	$2.600M
YoY Change	63.87%	19.23%	13.04%
Cash From Operating Activities	-$47.84M	-$179.4M	-$116.5M
YoY Change	23.64%	53.94%	39.27%
INVESTING ACTIVITIES
Capital Expenditures	$91.00K	$2.715M	$4.566M
YoY Change	-104.65%	-40.54%	137.07%
Acquisitions
YoY Change
Other Investing Activities	-$300.0K	-$20.21M	$45.48M
YoY Change	-100.54%	-144.44%	-1225.74%
Cash From Investing Activities	-$391.0K	-$22.93M	$40.51M
YoY Change	-100.73%	-156.59%	-665.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.053M	$9.085M
YoY Change		-33.37%	-119.84%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	18.62M	75.32M	149.0M
YoY Change	-52.19%	-49.45%	-13.58%
NET CHANGE
Cash From Operating Activities	-47.84M	-179.4M	-116.5M
Cash From Investing Activities	-391.0K	-22.93M	40.51M
Cash From Financing Activities	18.62M	75.32M	149.0M
Net Change In Cash	-29.62M	-127.0M	72.97M
YoY Change	-155.26%	-274.06%	-10.54%
FREE CASH FLOW
Cash From Operating Activities	-$47.84M	-$179.4M	-$116.5M
Capital Expenditures	$91.00K	$2.715M	$4.566M
Free Cash Flow	-$47.94M	-$182.1M	-$121.1M
YoY Change	30.47%	50.38%	41.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500000
CY2022	us-gaap	Tax Credit Carryforward Expiration Date TaxCreditCarryforwardExpirationDate	2028-12-31
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3427138
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3427138
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110494245
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101435505
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-35366
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5157386
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Kane Concourse
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 301
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Bay Harbor Islands
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33154
CY2022	dei	City Area Code CityAreaCode	781
CY2022	dei	Local Phone Number LocalPhoneNumber	652-4500
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	66379178
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Short Hills, NJ
CY2022	dei	Auditor Firm AuditorFirmId	185
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	178266000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	305744000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28208000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23112000
CY2022Q4	us-gaap	Inventory Net InventoryNet	14159000
CY2021Q4	us-gaap	Inventory Net InventoryNet	9862000
CY2022Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	138000
CY2021Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	678000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9661000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7066000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	230432000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	346462000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13020000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15066000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19991000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19005000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2688000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2220000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27197000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12552000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	973000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1198000
CY2022Q4	us-gaap	Assets Assets	294301000
CY2021Q4	us-gaap	Assets Assets	396503000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	97446000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	90660000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	728000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2611000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	722000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	345000
CY2022Q4	fbio	Warrant Liabilities Current WarrantLiabilitiesCurrent	13869000
CY2021Q4	fbio	Warrant Liabilities Current WarrantLiabilitiesCurrent	0
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2447000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2104000
CY2022Q4	fbio	Convertible Preferred Shares Current ConvertiblePreferredSharesCurrent	2052000
CY2021Q4	fbio	Convertible Preferred Shares Current ConvertiblePreferredSharesCurrent	0
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2948000
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	812000
CY2022Q4	fbio	Partner Company Installment Payments Licenses Current PartnerCompanyInstallmentPaymentsLicensesCurrent	7235000
CY2021Q4	fbio	Partner Company Installment Payments Licenses Current PartnerCompanyInstallmentPaymentsLicensesCurrent	4510000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	268000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	127715000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	101042000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	91730000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	42937000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21572000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20987000
CY2022Q4	fbio	Partner Company Installment Payments Licenses Noncurrent PartnerCompanyInstallmentPaymentsLicensesNoncurrent	1412000
CY2021Q4	fbio	Partner Company Installment Payments Licenses Noncurrent PartnerCompanyInstallmentPaymentsLicensesNoncurrent	3627000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1847000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2033000
CY2022Q4	us-gaap	Liabilities Liabilities	244276000
CY2021Q4	us-gaap	Liabilities Liabilities	170626000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2021Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2022Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3427138
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3427138
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110494245
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101435505
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	110000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	101000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	675841000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	656033000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-634233000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-547463000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	41721000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	108674000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	8304000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	117203000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50025000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	225877000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	294301000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	396503000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	70995000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	63134000
CY2022	fbio	Collaboration Revenue CollaborationRevenue	1882000
CY2021	fbio	Collaboration Revenue CollaborationRevenue	5389000
CY2022	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	192000
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	268000
CY2022	us-gaap	Other Income OtherIncome	2674000
CY2022	us-gaap	Revenues Revenues	75743000
CY2021	us-gaap	Revenues Revenues	68791000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	30775000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	32084000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	134199000
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	113240000
CY2022	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	677000
CY2021	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	15625000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	113656000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86843000
CY2022	fbio	Wire Transfer Fraud Loss WireTransferFraudLoss	0
CY2021	fbio	Wire Transfer Fraud Loss WireTransferFraudLoss	9540000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	279307000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	257332000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-203564000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-188541000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1398000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	649000
CY2022	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	13642000
CY2021	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	15308000
CY2022	fbio	Realized Gain Loss On Foreign Exchange RealizedGainLossOnForeignExchange	-89000
CY2022	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	0
CY2021	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	39294000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1129000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	447000
CY2022	fbio	Income From Grants IncomeFromGrants	1304000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9900000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	24188000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-213464000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-164353000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	449000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	473000
CY2022	us-gaap	Profit Loss ProfitLoss	-213913000
CY2021	us-gaap	Profit Loss ProfitLoss	-164826000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-127338000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-100123000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-86575000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-64703000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.97
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.97
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88874519
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	88874519
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81700220
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81700220
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	196999000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	19486000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	278000
CY2021	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	9085000
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock	8031000
CY2021	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	34996000
CY2021	fbio	Adjustments To Additional Paid In Capital Subsidiary At Market Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering	110887000
CY2021	fbio	Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram	309000
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	749000
CY2021	fbio	Partner Companys Exercise Of Options For Cash PartnerCompanysExerciseOfOptionsForCash	7000
CY2021	fbio	Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses	176000
CY2021	fbio	Common Shares Issued For Dividend On Partner Company Convertible Preferred Shares CommonSharesIssuedForDividendOnPartnerCompanyConvertiblePreferredShares	820000
CY2021	fbio	Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Shares AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredShares	21812000
CY2021	fbio	Adjustments To Additional Paid In Capital Conversion Of Derivative Warrant Liabilities AdjustmentsToAdditionalPaidInCapitalConversionOfDerivativeWarrantLiabilities	4628000
CY2021	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	100123000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-64703000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	225877000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	22987000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	174000
CY2022	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	6053000
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	8031000
CY2022	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	3205000
CY2022	fbio	Adjustments To Additional Paid In Capital Subsidiary At Market Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering	16370000
CY2022	fbio	Partner Companys Exercise Of Options For Cash PartnerCompanysExerciseOfOptionsForCash	142000
CY2022	fbio	Partner Companys Exercise Of Warrants For Cash PartnerCompanysExerciseOfWarrantsForCash	148000
CY2022	fbio	Adjustments To Additional Paid In Capital Reclassification Of Warrant Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity	89000
CY2022	fbio	Adjustments To Paid In Capital Partner Company Repurchases Of Stock AdjustmentsToPaidInCapitalPartnerCompanyRepurchasesOfStock	1105000
CY2022	fbio	Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram	206000
CY2022	us-gaap	Dividends Common Stock DividendsCommonStock	749000
CY2022	fbio	Adjustments To Paid In Capital Partner Company Redemption Of Preferred Shares AdjustmentsToPaidInCapitalPartnerCompanyRedemptionOfPreferredShares	85000
CY2022	fbio	Adjustments To Paid In Capital Miscellaneous Stock Adjustments AdjustmentsToPaidInCapitalMiscellaneousStockAdjustments	-6000
CY2022	fbio	Settlement Of Shares Withheld For Taxes SettlementOfSharesWithheldForTaxes	1698000
CY2022	fbio	Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses	-23000
CY2022	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	384000
CY2022	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	127338000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-86575000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50025000
CY2022	us-gaap	Profit Loss ProfitLoss	-213913000
CY2021	us-gaap	Profit Loss ProfitLoss	-164826000
CY2022	us-gaap	Depreciation Depreciation	3109000
CY2021	us-gaap	Depreciation Depreciation	2628000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-255000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	284000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	48000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2065000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3914000
CY2022	fbio	Accretion Of Partner Company Convertible Preferred Shares AccretionOfPartnerCompanyConvertiblePreferredShares	0
CY2021	fbio	Accretion Of Partner Company Convertible Preferred Shares AccretionOfPartnerCompanyConvertiblePreferredShares	2845000
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	770000
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	781000
CY2022	fbio	Debt Prepayment Penalties DebtPrepaymentPenalties	0
CY2021	fbio	Debt Prepayment Penalties DebtPrepaymentPenalties	450000
CY2022	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	4277000
CY2021	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	2474000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1967000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1689000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	22987000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	19486000
CY2022	fbio	Common Shares Issuable For Dividend On Partner Company S Convertible Preferred Shares CommonSharesIssuableForDividendOnPartnerCompanySConvertiblePreferredShares	0
CY2021	fbio	Common Shares Issuable For Dividend On Partner Company S Convertible Preferred Shares CommonSharesIssuableForDividendOnPartnerCompanySConvertiblePreferredShares	820000
CY2022	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	0
CY2021	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	39294000
CY2022	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	-1129000
CY2021	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	447000
CY2022	fbio	Research And Development Licenses Acquired Expense ResearchAndDevelopmentLicensesAcquiredExpense	642000
CY2021	fbio	Research And Development Licenses Acquired Expense ResearchAndDevelopmentLicensesAcquiredExpense	15625000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5380000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-768000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1744000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8458000
CY2022	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-540000
CY2021	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-66000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2595000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	309000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-344000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	185000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8349000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	43307000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1883000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2611000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	377000
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	345000
CY2022	fbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2025000
CY2021	fbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1856000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-186000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	84000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-179401000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-116540000
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	340000
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	11380000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2715000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4566000
CY2022	fbio	Proceeds From Sale Of Partner Company Property Plant And Equipment ProceedsFromSaleOfPartnerCompanyPropertyPlantAndEquipment	127000
CY2021	fbio	Proceeds From Sale Of Partner Company Property Plant And Equipment ProceedsFromSaleOfPartnerCompanyPropertyPlantAndEquipment	0
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	400000
CY2022	fbio	Proceeds From Sale Payments For Acquisition Of Vyne Products ProceedsFromSalePaymentsForAcquisitionOfVyneProducts	-20000000
CY2021	fbio	Proceeds From Sale Payments For Acquisition Of Vyne Products ProceedsFromSalePaymentsForAcquisitionOfVyneProducts	0
CY2022	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0
CY2021	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	56860000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22928000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	40514000
CY2022	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8031000
CY2021	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8031000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6053000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9085000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	174000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	278000
CY2022	fbio	Proceeds From Subsidiary S Employee Stock Purchase Plan ProceedsFromSubsidiarySEmployeeStockPurchasePlan	206000
CY2021	fbio	Proceeds From Subsidiary S Employee Stock Purchase Plan ProceedsFromSubsidiarySEmployeeStockPurchasePlan	309000
CY2022	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	749000
CY2021	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	749000
CY2022	fbio	Proceeds From Partner Companies Sale Of Stock And Warrants Net ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet	17835000
CY2021	fbio	Proceeds From Partner Companies Sale Of Stock And Warrants Net ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet	35367000
CY2022	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	16370000
CY2021	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	110803000
CY2022	fbio	Proceeds From Partner Company Share Settled Notes ProceedsFromPartnerCompanyShareSettledNotes	0
CY2021	fbio	Proceeds From Partner Company Share Settled Notes ProceedsFromPartnerCompanyShareSettledNotes	16971000
CY2022	fbio	Proceeds From Partner Company S Preferred Stock Offering ProceedsFromPartnerCompanySPreferredStockOffering	0
CY2021	fbio	Proceeds From Partner Company S Preferred Stock Offering ProceedsFromPartnerCompanySPreferredStockOffering	-13000
CY2022	fbio	Proceeds From Exercise Of Equity Grants ProceedsFromExerciseOfEquityGrants	290000
CY2021	fbio	Proceeds From Exercise Of Equity Grants ProceedsFromExerciseOfEquityGrants	7000
CY2022	fbio	Proceeds From Payments For Settlement Of Shares Withheld For Taxes ProceedsFromPaymentsForSettlementOfSharesWithheldForTaxes	-1698000
CY2021	fbio	Proceeds From Payments For Settlement Of Shares Withheld For Taxes ProceedsFromPaymentsForSettlementOfSharesWithheldForTaxes	0
CY2022	fbio	Refunds Of Payments For Payouts Of Reverse Stock Split Fractional Shares RefundsOfPaymentsForPayoutsOfReverseStockSplitFractionalShares	-6000
CY2021	fbio	Refunds Of Payments For Payouts Of Reverse Stock Split Fractional Shares RefundsOfPaymentsForPayoutsOfReverseStockSplitFractionalShares	0
CY2022	fbio	Proceeds From Issuance Of Payments For Redemptions Of Partner Company Preferred Stock ProceedsFromIssuanceOfPaymentsForRedemptionsOfPartnerCompanyPreferredStock	-85000
CY2021	fbio	Proceeds From Issuance Of Payments For Redemptions Of Partner Company Preferred Stock ProceedsFromIssuanceOfPaymentsForRedemptionsOfPartnerCompanyPreferredStock	0
CY2022	fbio	Proceeds From Issuance Of Payments For Redemptions Of Partner Company Common Stock ProceedsFromIssuanceOfPaymentsForRedemptionsOfPartnerCompanyCommonStock	-1105000
CY2021	fbio	Proceeds From Issuance Of Payments For Redemptions Of Partner Company Common Stock ProceedsFromIssuanceOfPaymentsForRedemptionsOfPartnerCompanyCommonStock	0
CY2022	fbio	Proceeds From Payments For Partner Company Deferred Financing Costs ProceedsFromPaymentsForPartnerCompanyDeferredFinancingCosts	-119000
CY2021	fbio	Proceeds From Payments For Partner Company Deferred Financing Costs ProceedsFromPaymentsForPartnerCompanyDeferredFinancingCosts	0
CY2022	fbio	Proceeds From Payments For Debt Issuance Costs Related To Oaktree Note ProceedsFromPaymentsForDebtIssuanceCostsRelatedToOaktreeNote	0
CY2021	fbio	Proceeds From Payments For Debt Issuance Costs Related To Oaktree Note ProceedsFromPaymentsForDebtIssuanceCostsRelatedToOaktreeNote	-95000
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	0
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	10450000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5000000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5300000
CY2022	fbio	Proceeds From Issuance Of Partner Company Convertible Preferred Shares ProceedsFromIssuanceOfPartnerCompanyConvertiblePreferredShares	2533000
CY2021	fbio	Proceeds From Issuance Of Partner Company Convertible Preferred Shares ProceedsFromIssuanceOfPartnerCompanyConvertiblePreferredShares	0
CY2022	fbio	Payment Of Debt Issuance Costs Associated With Partner Company Share Settled Notes PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes	597000
CY2021	fbio	Payment Of Debt Issuance Costs Associated With Partner Company Share Settled Notes PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes	0
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	47112000
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	5000000
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	7000000
CY2022	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	2864000
CY2021	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	6188000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	75319000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	148994000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-127010000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72968000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	307964000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	234996000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180954000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	307964000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	9419000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	6918000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	858000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	993000
CY2022	fbio	Settlement Of Restricted Shares Units Into Common Stock SettlementOfRestrictedSharesUnitsIntoCommonStock	5000
CY2021	fbio	Settlement Of Restricted Shares Units Into Common Stock SettlementOfRestrictedSharesUnitsIntoCommonStock	3000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.33
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.04
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1270000
CY2022	fbio	Conversion Of Partner Company Convertible Preferred Shares ConversionOfPartnerCompanyConvertiblePreferredShares	0
CY2021	fbio	Conversion Of Partner Company Convertible Preferred Shares ConversionOfPartnerCompanyConvertiblePreferredShares	21812000
CY2022	fbio	Conversion Of Partner Company Derivative Warrant Liabilities ConversionOfPartnerCompanyDerivativeWarrantLiabilities	0
CY2021	fbio	Conversion Of Partner Company Derivative Warrant Liabilities ConversionOfPartnerCompanyDerivativeWarrantLiabilities	4628000
CY2022	fbio	Conversion Of Maintenance Fees To Promissory Notes ConversionOfMaintenanceFeesToPromissoryNotes	268000
CY2021	fbio	Conversion Of Maintenance Fees To Promissory Notes ConversionOfMaintenanceFeesToPromissoryNotes	0
CY2022	fbio	Unpaid Partner Company Intangible Assets UnpaidPartnerCompanyIntangibleAssets	4740000
CY2021	fbio	Unpaid Partner Company Intangible Assets UnpaidPartnerCompanyIntangibleAssets	0
CY2022	fbio	Unpaid Partner Companys Debt Offering Cost UnpaidPartnerCompanysDebtOfferingCost	1058000
CY2021	fbio	Unpaid Partner Companys Debt Offering Cost UnpaidPartnerCompanysDebtOfferingCost	214000
CY2022	fbio	Unpaid Partner Company Offering Cost UnpaidPartnerCompanyOfferingCost	4000
CY2021	fbio	Unpaid Partner Company Offering Cost UnpaidPartnerCompanyOfferingCost	371000
CY2022	fbio	Unpaid Partner Company Repurchases Of Stock UnpaidPartnerCompanyRepurchasesOfStock	0
CY2021	fbio	Unpaid Partner Company Repurchases Of Stock UnpaidPartnerCompanyRepurchasesOfStock	0
CY2022	fbio	Adjustments To Paid In Capital Miscellaneous Retained Earnings Adjustments AdjustmentsToPaidInCapitalMiscellaneousRetainedEarningsAdjustments	195000
CY2021	fbio	Adjustments To Paid In Capital Miscellaneous Retained Earnings Adjustments AdjustmentsToPaidInCapitalMiscellaneousRetainedEarningsAdjustments	0
CY2022	fbio	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	89000
CY2021	fbio	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	0
CY2022	fbio	Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes	90000
CY2021	fbio	Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes	362000
CY2022	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	384000
CY2021	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	0
CY2022	fbio	Unpaid Research And Development License Acquired UnpaidResearchAndDevelopmentLicenseAcquired	325000
CY2021	fbio	Unpaid Research And Development License Acquired UnpaidResearchAndDevelopmentLicenseAcquired	250000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2953000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	207000
CY2022	fbio	Number Of Partner Companies That Are Publicly Traded NumberOfPartnerCompaniesThatArePubliclyTraded	4
CY2022	fbio	Number Of Partner Companies That Have Consummated Strategic Partnerships With Industry Leaders NumberOfPartnerCompaniesThatHaveConsummatedStrategicPartnershipsWithIndustryLeaders	3
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, provisions for product returns, coupons, rebates, chargebacks, discounts, allowances and distribution fees paid by Journey to certain wholesalers, inventory realization, useful lives assigned to long-lived assets and amortizable intangible assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</p>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	178266000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	305744000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2688000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2220000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180954000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	307964000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	400000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Inventory Net InventoryNet	9862000
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	6454000
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	5572000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	395000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7739000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4290000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	429000
CY2022Q4	us-gaap	Inventory Net InventoryNet	14159000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25466000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24460000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12446000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9394000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13020000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15066000
CY2022	us-gaap	Depreciation Depreciation	3100000
CY2021	us-gaap	Depreciation Depreciation	2600000
CY2021	fbio	Change In Warrant Liability Contingent Payment ChangeInWarrantLiabilityContingentPayment	-4628000
CY2022Q4	fbio	Warrant Liabilities Current WarrantLiabilitiesCurrent	13869000
CY2022	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	700000
CY2021	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	15600000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	368344
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	9320000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	7063000
CY2022Q4	fbio	Decrease In Note Payable DecreaseInNotePayable	0
CY2021Q4	fbio	Decrease In Note Payable DecreaseInNotePayable	10450000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	91730000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	42937000
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	10417000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2065000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	12482000
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	11394000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3914000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	15308000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	57244000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	47429000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1693000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1835000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	9772000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8809000
CY2022Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	7390000
CY2021Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	7932000
CY2022Q4	fbio	Accrued Research And Development Expense License Maintenance Fees AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees	632000
CY2021Q4	fbio	Accrued Research And Development Expense License Maintenance Fees AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees	4640000
CY2022Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	4600000
CY2021Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	850000
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2627000
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3833000
CY2022Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	7604000
CY2021Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	10603000
CY2022Q4	fbio	Accrued Return Reserve Current AccruedReturnReserveCurrent	3689000
CY2021Q4	fbio	Accrued Return Reserve Current AccruedReturnReserveCurrent	3240000
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	342000
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1853000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1489000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	97446000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	90660000
CY2022Q4	fbio	Minority Interest Equity Share MinorityInterestEquityShare	135642000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-127338000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	8304000
CY2021Q4	fbio	Minority Interest Equity Share MinorityInterestEquityShare	217326000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-100123000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	117203000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22634754
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21904246
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110494245
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101435505
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P10Y
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22987000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19486000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1053490
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.02
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	647482
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y7M17D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	35000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1018490
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y8M4D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2002500
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.54
CY2022	fbio	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	230000
CY2022	fbio	Share Based Compensation Arrangement Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementOptionsGrantedWeightedAverageRemainingContractualTerm	P6Y11M23D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	370000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.27
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2650990
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.47
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	230000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y7M20D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	650990
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.34
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y6M18D
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0378
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0104
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0150
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7848
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.0065
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.0271
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	100000
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4590621
CY2020Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	3.17
CY2020Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	607848
CY2020	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P4Y10M6D
CY2021	fbio	Class Of Warrant Or Right Number Of Shares Granted ClassOfWarrantOrRightNumberOfSharesGranted	-60000
CY2021	fbio	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	1.37
CY2021	fbio	Class Of Warrant Or Right Granted Weighted Average Intrinsic Value ClassOfWarrantOrRightGrantedWeightedAverageIntrinsicValue	0
CY2021	fbio	Class Of Warrant Or Right Number Of Shares Forfeited ClassOfWarrantOrRightNumberOfSharesForfeited	25000
CY2021	fbio	Class Of Warrant Or Right Forfeited Weighted Average Exercise Price ClassOfWarrantOrRightForfeitedWeightedAverageExercisePrice	3.00
CY2021	fbio	Class Of Warrant Or Right Forfeited Weighted Average Intrinsic Value ClassOfWarrantOrRightForfeitedWeightedAverageIntrinsicValue	0
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4505621
CY2021Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	3.20
CY2021Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	68800
CY2021	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P3Y11M4D
CY2022	fbio	Class Of Warrant Or Right Number Of Shares Expired ClassOfWarrantOrRightNumberOfSharesExpired	2596171
CY2022	fbio	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	3.26
CY2022	fbio	Class Of Warrant Or Right Expired Weighted Average Intrinsic Value ClassOfWarrantOrRightExpiredWeightedAverageIntrinsicValue	0
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1909450
CY2022Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	3.11
CY2022Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	0
CY2022	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P7Y5M12D
CY2022	fbio	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	1774450
CY2022	fbio	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	3.19
CY2022	fbio	Class Of Warrant Or Right Exercisable Weighted Average Intrinsic Value ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue	0
CY2022	fbio	Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Life ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife	P7Y7M9D
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	24000000.0
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20000000.0
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	2000000.0
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2100000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	3524000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	3253000
CY2022	us-gaap	Sublease Income SubleaseIncome	2127000
CY2021	us-gaap	Sublease Income SubleaseIncome	1835000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	648000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	727000
CY2022	us-gaap	Lease Cost LeaseCost	2045000
CY2021	us-gaap	Lease Cost LeaseCost	2145000
CY2022	fbio	Lessee Lease Portfolio And Other Supplemental Lease Information LesseeLeasePortfolioAndOtherSupplementalLeaseInformation	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables summarize quantitative information about the Company’s operating leases:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,473)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,366)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets exchanged for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term – operating leases (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate – operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p>
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	3473000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3366000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2953000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	207000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.066
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3550000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3665000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4134000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3879000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3572000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	12486000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	31286000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7267000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	24019000
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1100000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000
CY2022Q4	us-gaap	Dividends Receivable DividendsReceivable	3866000
CY2021Q4	us-gaap	Dividends Receivable DividendsReceivable	12327000
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	192000
CY2021Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	215000
CY2022Q4	fbio	Deferred Tax Assets Business Interest Expense Deduction Limit DeferredTaxAssetsBusinessInterestExpenseDeductionLimit	2359000
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	420000
CY2022	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2021	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2022	fbio	Annual Management Services Agreement Fee Income AnnualManagementServicesAgreementFeeIncome	5000000
CY2021	fbio	Annual Management Services Agreement Fee Income AnnualManagementServicesAgreementFeeIncome	4500000
CY2022	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2021	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	449000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	473000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	449000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	473000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	318000000.0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	198250000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	180994000
CY2022Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	30151000
CY2021Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	31556000
CY2022Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	334000
CY2021Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	384000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	13754000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	13560000
CY2022Q4	fbio	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7011000
CY2021Q4	fbio	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6965000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3402000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2265000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	33501000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	23239000
CY2022Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	42000
CY2021Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	49000
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	406000
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2021Q4	fbio	Deferred Tax Assets Business Interest Expense Deduction Limit DeferredTaxAssetsBusinessInterestExpenseDeductionLimit	7000
CY2022Q4	fbio	Deferred Tax Assets Reserve On Sales Return Discount And Bad Debt DeferredTaxAssetsReserveOnSalesReturnDiscountAndBadDebt	2286000
CY2021Q4	fbio	Deferred Tax Assets Reserve On Sales Return Discount And Bad Debt DeferredTaxAssetsReserveOnSalesReturnDiscountAndBadDebt	1883000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	325858000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	261537000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	317959000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	251052000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7899000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10485000
CY2022Q4	fbio	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	5835000
CY2021Q4	fbio	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	5732000
CY2022Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	1625000
CY2021Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	4753000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0700
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.1000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0400
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0400
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0300
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0100
CY2022	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	-0.0200
CY2021	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0.0100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2900
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.0200
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0100
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	fbio	Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn	0.80
CY2022	fbio	Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn	0.80
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	67000000.0
CY2022	us-gaap	Revenues Revenues	75743000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	30775000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	134876000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	113656000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9900000
CY2022	us-gaap	Profit Loss ProfitLoss	-213913000
CY2021	us-gaap	Revenues Revenues	68791000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	32084000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	128865000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86843000
CY2021	fbio	Wire Transfer Fraud Loss WireTransferFraudLoss	9540000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	24188000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	473000
CY2021	us-gaap	Profit Loss ProfitLoss	-164826000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27197000
CY2022Q4	fbio	Tangible Assets Net TangibleAssetsNet	267104000
CY2022Q4	us-gaap	Assets Assets	294301000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12552000
CY2021Q4	fbio	Tangible Assets Net TangibleAssetsNet	383951000
CY2021Q4	us-gaap	Assets Assets	396503000
CY2022	fbio	Collaboration Revenue CollaborationRevenue	1882000
CY2021	fbio	Collaboration Revenue CollaborationRevenue	5389000
CY2022	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	192000
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	268000
CY2022	us-gaap	Other Income OtherIncome	2674000
CY2021	us-gaap	Other Income OtherIncome	0
CY2022	us-gaap	Revenues Revenues	75743000
CY2021	us-gaap	Revenues Revenues	68791000

Files In Submission

Name	View Source	Status
fbio-20221231_cal.xml	Edgar Link	unprocessable
0001558370-23-005282-index-headers.html	Edgar Link	pending
0001558370-23-005282-index.html	Edgar Link	pending
0001558370-23-005282.txt	Edgar Link	pending
0001558370-23-005282-xbrl.zip	Edgar Link	pending
fbio-20221231.xsd	Edgar Link	pending
fbio-20221231x10k.htm	Edgar Link	pending
fbio-20221231x10k002.jpg	Edgar Link	pending
fbio-20221231xex21d1.htm	Edgar Link	pending
fbio-20221231xex23d1.htm	Edgar Link	pending
fbio-20221231xex23d1001.jpg	Edgar Link	pending
fbio-20221231xex31d1.htm	Edgar Link	pending
fbio-20221231xex31d2.htm	Edgar Link	pending
fbio-20221231x10k_htm.xml	Edgar Link	completed
fbio-20221231xex32d1.htm	Edgar Link	pending
fbio-20221231xex32d2.htm	Edgar Link	pending
fbio-20221231xex4d3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
fbio-20221231_def.xml	Edgar Link	unprocessable
fbio-20221231_lab.xml	Edgar Link	unprocessable
fbio-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2022 Q4 Form 10-K Financial Statement

#000155837023005282 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2022 Q4 Form 10-K Financial Statement

#000155837023005282 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio